RXi Pharmaceuticals Corp (NASDAQ: RXII) is headed up in the market this morning after announcing that it will soon present new data from its Dermatology Franchise. Any time new data hits the tape when it comes to publicly traded biotech companies, we can expect to see movement, and today’s news is no different as the stock rockets. Today, we’ll talk about:
- The coming data presentation
- what we’re seeing from the stock as a result;
- and what we’ll be watching with regard to RXII ahead.
RXII Announces Coming Data Presentation
As mentioned above, RXi Pharmaceuticals Corp hit the ground running when the opening bell rang today after announcing the coming presentation of data. In a press release issued early this morning, the company announced that it will present new data from its Dermatology Franchise at the International Investigative Dermatology (IDD) Conference.
In the release, RXII explained that the conference unites three leading dermatology societies, including the European Society of Dermatological Research (ESDR), the Journal of Investigative Dermatology (JSID), and the Society of Investigational Dermatology (SID). These meetings only take place once every five years and are a key platform for Dermatological breakthroughs.
This year will be the seventh time the IID has held a meeting. At the meeting, scientists and industry leaders from across the world will exchange information and create potential collaborations. The meeting will be held from May 16 through May 19 at Rosen Shingle Creek Resort in Orlando, FL. During the meeting, RXII will be providing 3 poster presentations.
, Mass., April 4, 2018 /PRNewswire/ — RXi Pharmaceuticals Corporation, a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present new data from the Company’s Dermatology Franchise at the International Investigative Dermatology (IID) Conference. This conference unites three leading dermatology societies, the European Society of Dermatological Research (ESDR), the Journal of Investigative Dermatology (JSID) and the Society of Investigational Dermatology (SID), into one meeting that takes place every five years. The 2018 IID will hold its seventh meeting this year, where scientists and industry leaders gather from across the world to exchange information and facilitate collaboration. This meeting is being held May 16-19, 2018 at Rosen Shingle Creek Resort in Orlando, Florida.
During the meeting, RXi Pharmaceuticals Corp will host 3 poster presentations. One discussing RXI-109 as a treatment to reduce the formation of hypertrophic dermal scars, the next discussing SamcyproneTM for the treatment of Warts, and the third discussing the topical Administration of self-delivering RNAi compounds for the reduction of Hyperpigmentation.
What We’re Seeing From The Stock
With the news that RXII will be presenting at the IID conference, it’s no surprise that investors are excited. Not only does this mean that new data must be positive as it was accepted for a presentation at this elite event, it also means that the company’s leadership will have a platform to mingle with other companies in the space, forming potential collaborations that could become key value drivers. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:38), RXII is trading at $3.37 per share after a gain of $0.72 per share or 27.17% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on RXII. In particular, we’re interested in learning more about the new data that will be released at the IID conference as well as following the company’s progress with regard to its robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!